Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05801094 | A Phase I Study of QL1604 for Advanced Solid Tumors | unknown | Phase 1 | 71 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05539157 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | unknown | Phase 1 | 1 | Immorna Biotherapeutics, Inc.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) |
| unknown |
| Phase 1 |
| 21 |
| BGI, ChinaOTHER |
| 1 |
| Apr 4, 2023 |
| clinicaltrials |
| NCT05785728 | A Study of DB-1202 Monotherapy in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | DualityBio Inc.INDUSTRY | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05790447 | Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04522284 | PRECISE CURATE.AI Pilot Clinical Trial | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04542863 | The Molecular Imaging Research of F-18 Labeled DX600 PET Probe | unknown | N/A | 100 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04053673 | Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | unknown | Phase 1 | 130 | Ribon Therapeutics, Inc.INDUSTRY | 2 | Mar 28, 2023 | clinicaltrials |
| NCT04214717 | Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor(DC-CIK) | unknown | N/A | 60 | Yantai Yuhuangding HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT04214730 | Study of NK Combined With Chemotherapy for Advanced Solid Tumor(NK) | unknown | N/A | 60 | Yantai Yuhuangding HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05785052 | Biomarkers of Renal Cancer(BRC) | unknown | — | 1,000 | Biorek S.R.L.INDUSTRY | 2 | Mar 27, 2023 | clinicaltrials |
| NCT05775666 | UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 87 | Peking UniversityOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05434299 | A Study of TFX05-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 36 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05768321 | Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation | unknown | Phase 1 | 70 | GenEros Biopharma Hangzhou LtdINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT04947033 | A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors | unknown | Phase 1 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05759234 | A Study of HS248 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 24 | Hanhui Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | unknown | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05692466 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")(DINOSAur) | unknown | — | 572 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05703243 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")(DINOSAur II) | unknown | — | 572 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05554666 | A Study of ASKG315 in Patients With Advanced Solid Tumors. | unknown | Phase 1 | 56 | AskGene Pharma, Inc.INDUSTRY | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05748938 | A Study of RD14-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05744089 | Home Management of Simple Hydromorphone PCA Pump Mode | unknown | N/A | 50 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05745454 | A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors | unknown | N/A | 12 | su haichuanOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT04768868 | The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors(WEE1) | unknown | Phase 1 | 350 | Impact Therapeutics, Inc.INDUSTRY | 3 | Feb 24, 2023 | clinicaltrials |
| NCT05740215 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 158 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04930354 | ECP-1014 Treatment for Patients With Solid Tumor Cancers | unknown | Phase 1 | 29 | Euclises Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05276609 | ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 177 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05538676 | Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors | unknown | — | 10 | Xiaohua ZhuOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05724732 | Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors | unknown | Early Phase 1 | 24 | RenJi HospitalOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05537051 | A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours | unknown | Phase 1 | 30 | Biotheus Inc.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05583201 | NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05706207 | A Study of HB0030 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05584709 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | unknown | Phase 1 | 34 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05234853 | Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Purinomia Biotech, Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05537987 | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | InnoCare Pharma Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04900519 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 100 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05673538 | TT-00973-MS Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05642949 | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 400 | Minghui Pharmaceutical Pty LtdINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | unknown | Phase 2 | 200 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05666635 | Study of LTC004 in Subjects With Advanced Malignant Tumors | unknown | Phase 1 | 368 | LetolabINDUSTRY | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | unknown | Phase 2 | 64 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05649163 | Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | unknown | — | 306 | Shen LinOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05649618 | TIL Cells for the Treatment of the Advanced Solid Tumors Patients | unknown | Early Phase 1 | 42 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05649761 | A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 61 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04614740 | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05648994 | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | unknown | Early Phase 1 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 13, 2022 | clinicaltrials |
| NCT05644509 | Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | unknown | Phase 1 | 10 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2023source: clinicaltrials